You are here: Industry Insights > Boston Scientific

News List

Boston Scientific to sell BTG Specialty Pharmaceuticals business for $800m pharmaceutical-technology
December 03, 2020
Boston Scientific has signed a definitive agreement with SERB’s affiliates, Stark International and SERB SAS, to divest its BTG Specialty Pharmaceuticals business for $800m in cash.
Boston Scientific Initiates Trial to Evaluate WATCHMAN FLX as Treatment for Risk of Stroke americanpharmaceuticalreview
November 09, 2020
Boston Scientific has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device within a broad population of patients with non-valvular atrial fibrillation (NVAF) ...
Boston Scientific Receives FDA Approval for the Ranger Drug-Coated Balloon americanpharmaceuticalreview
November 05, 2020
Boston Scientific has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal ...
Boston Scientific considers sale of speciality pharmaceutical unit pharmaceutical-technology
July 16, 2020
Boston Scientific is considering the divestiture of its speciality pharmaceutical business, focused on snake venom treatments, reported Bloomberg citing people familiar with the matter.
Boston Scientific announces FDA approval Of ImageReady MRI biospectrumasia
August 25, 2019
Boston Scientific Announces FDA Approval Of ImageReady™ MRI For Vercise Gevia™ Deep Brain Stimulation System
Boston Scientific Closes Acquisition of BTG americanpharmaceuticalreview
August 20, 2019
Boston Scientific Corporation has announced the completion of its acquisition of BTG plc. pursuant to the previously announced scheme of arrangement. BTG develops and commercializes products used in ...
Varian inks bead agreement with Boston Scientific for cancer care biospectrumasia
July 08, 2019
Varian, a US based leader in developing and delivering cancer care solutions, has announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating art
Boston Scientific to acquire Vertfilex for $465M biospectrumasia
May 13, 2019
Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies
The top 10 medtech companies of 2024 fiercebiotech
January 03, 2019
While most of the world’s top 10 medtech companies are expected to defend their relative rankings in the coming years, ambitious or inspired M&A deals could give companies lower on the list the oomph to move up and ......
FDA OKs Boston Sci’s Eluvia drug-eluting stent for PAD fiercebiotech
September 27, 2018
Made of wire mesh, the Eluvia stent has a drug-polymer coating that releases paclitaxel for one year. It is designed to stop tissue regrowth that could block the artery.

Previous page 1 2 Next page